Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older. For beta thalassaemia, ... Overview · Product information · Authorisation details

Casgevy is indicated for the treatment of severe sickle cell disease (SCD) in patients 12 years of age and older with recurrent vaso-occlusive crises (VOCs) for ...

15 дек. 2023 г. · Casgevy (exagamglogene autotemcel) is indicated for the treatment of transfusion‐dependent beta thalassemia and severe sickle cell disease in patients 12 years ...

10 мая 2024 г. · Casgevy was deemed eligible for the EMA's PRIority MEdicines (PRIME) scheme in 2020 for treating sickle cell disease. PRIME offers medicine ...

13 февр. 2024 г. · CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso- ...

31 мар. 2024 г. · CASGEVY's EPAR, including its plain-language summary, available on the EMA website under the medicine's webpage: link to the EPAR summary ...

15 дек. 2023 г. · A European Medicines Agency committee has endorsed Vertex and CRISPR Therapeutics' Casgevy for sickle cell disease and transfusion‐dependent beta thalassemia.

CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso- ...

13 февр. 2024 г. · The CRISPR treatment is the first gene therapy approved in Europe for sickle cell disease and transfusion-dependent beta-thalassemia (TDT).

26 февр. 2024 г. · On February 13th 2024, the European Commission granted authorization to CASGEVY – the first CRISPR/Cas9-based gene therapy produced by ...